Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Shareholder Meeting (September 2022)
13 slides from Valiant Organics's shareholder meeting presentation, Sep 28, 2022
Slide 1: Valiant Organics Limited
•••• Valiant Organics Limited September 28, 2022 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza", Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Sandra (E), Mu
Slide 2: 17th Annual General Meeting
17th ANNUAL GENERAL MEETING 28 SEPTEMBER 2022 1
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 28,800 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket Ammonolysis Hydrogenation Key Products: Industries Served: 31% Key Products: Industries Served: • Para Nitro Aniline • Dyes • Ortho Anisidine • Dyes • Ortho Chloro Para Nitro Aniline • Pigments • Para Anisidine • Pigments • IPPCA • Pharmaceutical • Meta Chloro Aniline
Slide 6: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 7: Financial Overview
sece liant ics 9000 FINANCIAL OVERVIEW
Slide 8: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 14,000 2,300 80.00% 1,500 80.00% 2,052 2,049 11,533 70.00% 70.00% 2,000 12,000 1,798 1,803 10,000 60.00% 60.00% 1,700 7,548 50.00% 50.00% 8,000 6,923 6,749 1,400 40.00%
Slide 9: Strategic Overview
sece liant ics 9000 STRATEGIC OVERVIEW
Slide 10: Advantage India
Key Growth Factors CHINA +1 OPPORTUNITIES POLICY INCREASING ADVANTAGE INDIA SUPPORT INVESTMENT • Global companies looking to • Indian specialty chemicals (22% • The government plans to • India’s specialty chemical broad base their procurement of total chemicals) grew at CAGR introduce production-lin
Slide 11: Completed & On-Going Projects
Completed & On-Going Projects Installed Capacity Approx. Capex Product Project Status Remarks (MT per month) (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress
Slide 12: FY 2022-23 Roadmap
FY 2022-23 Roadmap Target Revenue Growth of 30%+ Increase Margin Profile Stabilise and Scale up PAP project Enhancing other Production Capacities Moderate Production Costs Strengthen Supply Chain Widen Product Mix Enhance Customer Base Focus on Debottlenecking Improve Returns on Capital Employed & E
Slide 13: Thank You
sece liant ics 9000 THANK YOU
Valiant Organics — Shareholder Meeting (September 2022) on 6ix